|
Iran Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Iran Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Iran.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Iranian pharmaceutical and healthcare industry.
Competitive intelligence, Iranian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Iranian market.
The Iran Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Iran Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Iranian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Iran to test other views – a key input for successful budgeting and strategic business planning in the Iranian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Iranian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iran.
- Exploit The Latest Competitive Iranian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Iran.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Iran Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Table: Iran Pharmaceuticals And Healthcare Industry SWOT |
| Iran Political SWOT |
| Iran Economic SWOT |
| Iran Business Environment SWOT |
Chapter - Business Environment Ranking |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Registration Of Imports |
| Generic Registration |
| Intellectual Property (IP) Regime |
| Intellectual Property Disputes |
| Counterfeit Medicines |
| Pricing And Reimbursement |
| Recent Pricing And Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| HIV/AIDS Situation |
| Table: Iran HIV/AIDS Prevalence |
| Healthcare Sector |
| Primary Care |
| Secondary Care |
| Health Insurance |
| Regional Developments |
| International Healthcare Collaboration |
| Pharmaceutical Industry |
| Pharmaceutical Industry Recent Developments |
| Traditional Herbal Remedies |
| Recent Company Activity |
| Retail Pharmacies |
| Research And Development |
| International Pharmaceutical Collaboration |
Chapter - Industry Forecast Scenario |
| Overall Drug Market Forecast |
| Table: Iran – Drug Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated) |
| Industry Growth Factors |
| Table: Iran – Health Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated) |
| Macroeconomic Growth Factors |
| Table: Iran – Economic Activity |
| Prescription Drug Market Forecast |
| Table: Iran – Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated) |
| OTC Drug Market Forecast |
| Table: Iran – OTC Market Data Forecasts, 2003-2013 (US$mn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Iran – Patented Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) |
| Generic Drug Market Forecast |
| Table: Iran – Generics Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) |
| Medical Device Market Forecast |
| Table: Iran – Medical Device Market Forecast, 2006-2013 (US$mn unless otherwise stated) |
| Import/Export Market Forecast |
| Table: Iran – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Iran – Other Health Indicators, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinationals |
| Novartis |
| Merck & Co |
| Pfizer |
| GlaxoSmithKline |
| Sanofi-Aventis |
| Indigenous Companies |
| Darou Pakhsh |
| Caspian Tamin Pharmaceutical Company* |
| Pharmieco |
| Pars Darou |
| Zahravi |
| Amin |
| Sina Darou Pharmaceutical Company |
| Exir Pharmaceuticals |
Chapter - Country Snapshot: Iran Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1996-2005 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
|
Iran Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI is forecasting a 10.2% compound annual growth rate (CAGR) for the Iranian pharmaceutical market, meaning an increase in total value from US$2.25bn in 2008 to US$3.65bn by 2013. We believe the main drivers for growth will include a growing population, a rise in domestic drug manufacturing, and the greater burden of disease imposed by respiratory illnesses. Total healthcare spending is expected to rise from US$24.3bn in 2008, to US$50.0bn by 2013, reflecting the increasing demand on medical services.
The prevalence of respiratory diseases and cancers in Iran is increasing at a significant rate, according to the Tehran Times. The Behesht-e Zahra Organisation conducted a demographic study in Tehran during 2007-2008 to determine the scale of the problem. During this period, 762 people died from lung cancer in Tehran, while 291 people died from respiratory diseases. Over two thirds of those dying from respiratory related disease in the capital were men. A further 401 people have died from lung cancer during 2008- 2009, with more expected be added to this number pending an additional consensus on figures available.
According to BMI's Burden of Disease Database (BoDD), the number of disability-adjusted life years (DALYs) lost to lung cancer will increase to 142,934 by 2030, from 71,937 in 2009. Significantly, the proportion of lung cancers to the total cancer burden in Iran will rise from 14.3% in 2009 to 18.0% by 2030.
During February 209, the Iranian government announced the addition of new prescription drugs for multiple sclerosis (MS) and anaemia. The new drugs launched in Iran for the treatment of MS are believed to include an interferon beta-1b. No originator names have been disclosed, however it is possible that the likely candidate is Betaseron manufactured by Bayer Healthcare. Stunningly, a version of fingolimod by Novartis has been launched as well as a biosimilar version of EMD Serono's Rebif. The Iranian pharmaceutical firm CinnaGen Biopharma is rumoured to be releasing another interferon beta- 1a preparation, despite its first MS drug CinnoVex already available in the country.
Iranian pharmaceutical manufacturers are disadvantaged by the government's poor intellectual property protection regime. Developing a molecule for combination therapies may qualify for patent protection in other countries. However, while weak patent law adherence continues in Iran, BMI expects this will create significant barriers for Iranian companies prospecting trade on the global market. BMI cautions that inaccurate reporting and contrasting interpretations are indicative of emerging markets. Additionally, Iran's track record for irregularities in its pharmaceutical policies presents difficulties in accurately assessing the drug sector.
Iran's growing population and increased demand for healthcare has led to growing investment in drug manufacturing plants, which will contribute to the rise in exports. As foreign investment is limited by government rules, BMI encourages the development of local production facilities, which will reduce Iran's reliance on imported patented products.
|
Iran Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |